VITamin D and OmegA-3 TriaL (VITAL)
Source: View publication →
In a large, randomized, placebo-controlled trial of generally healthy adults, neither vitamin D3 (2000 IU/day) nor marine omega-3 fatty acids (1 g/day) significantly reduced the incidence of major cardiovascular events or invasive cancer over a median follow-up of 5.3 years.
Key Findings
Study Design
Study Limitations
Clinical Significance
The VITAL trial provides robust evidence against the universal supplementation of vitamin D or marine omega-3 fatty acids for the primary prevention of cancer and cardiovascular disease in the general adult population, suggesting that such supplementation does not provide the anticipated clinical benefits in healthy individuals.
Historical Context
Prior to VITAL, significant observational and small-scale trial data suggested potential benefits of vitamin D and omega-3 fatty acids for cardiovascular and cancer prevention. VITAL was designed to address these hypotheses definitively in a large, diverse cohort to clarify the role of these supplements in primary prevention, ultimately challenging prevailing expectations and informing subsequent clinical guidelines.
Guided Discussion
High-yield insights from every perspective
Based on the biological mechanisms of Vitamin D and Omega-3 fatty acids (anti-inflammatory and anti-proliferative effects), why was it hypothesized that these supplements would reduce the incidence of cancer and cardiovascular disease?
Key Response
Vitamin D is thought to inhibit cell proliferation and promote differentiation, potentially slowing carcinogenesis. Omega-3 fatty acids (EPA and DHA) are precursors to anti-inflammatory resolvins and can lower triglyceride levels, which are theoretical mechanisms for reducing atherosclerosis and systemic inflammation.
A healthy 65-year-old patient with no history of heart disease or cancer asks if they should start taking 2000 IU of Vitamin D3 and 1g of fish oil daily to 'stay healthy.' How do the VITAL trial results guide your evidence-based recommendation?
Key Response
According to VITAL, neither Vitamin D3 (2000 IU/day) nor marine omega-3 fatty acids (1 g/day) significantly reduced the primary endpoints of major cardiovascular events or invasive cancer in a general primary prevention population. Therefore, routine supplementation for the sole purpose of preventing these diseases in healthy adults is not supported by this evidence.
The VITAL trial showed a non-significant result for the primary composite cardiovascular endpoint, but noted a potential signal for reduced myocardial infarction in the omega-3 group (HR 0.72). How do you reconcile this with the results of the REDUCE-IT trial regarding dose and formulation?
Key Response
REDUCE-IT used a much higher dose (4g/day) of purified icosapent ethyl in a high-risk population, whereas VITAL used 1g/day of a combined EPA/DHA product in a primary prevention population. The VITAL MI signal suggests that while low-dose n-3 may have some benefit, the magnitude of effect seen in high-risk patients requires higher, purified doses as demonstrated in subsequent specialty-driven trials.
When teaching medical students about the interpretation of VITAL's secondary endpoints—such as the reduction in cancer mortality (but not incidence) seen in the Vitamin D arm after excluding the first two years of follow-up—what cautions should you provide regarding 'p-hacking' and post-hoc analyses?
Key Response
It is critical to teach that secondary analyses are hypothesis-generating. Excluding early follow-up time (latency analysis) is biologically plausible for cancer but increases the risk of Type I error. These findings must be viewed with skepticism until replicated in a trial where they are the primary pre-specified endpoint.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
VITAL employed a 2x2 factorial design. What are the specific statistical risks associated with this design if an interaction between Vitamin D and Omega-3 exists, and how does the study address the 'marginal' vs. 'simple' effects of the interventions?
Key Response
Factorial designs assume no interaction between the two interventions. If Vitamin D and Omega-3 worked synergistically or antagonistically, the 'marginal effect' (comparing all D to all placebo-D) would be a biased estimate of the treatment effect. VITAL's authors tested for interaction terms and found none, justifying the 'two-trials-in-one' efficiency of the design.
As a reviewer, how would you critique the inclusion of a generally healthy, non-deficient population in VITAL (mean baseline 25-hydroxyvitamin D was 31 ng/mL) regarding its ability to detect a treatment effect for Vitamin D?
Key Response
A 'tough' reviewer would argue that a nutrient trial is likely to fail if the participants are already 'replete' at baseline. If Vitamin D only prevents cancer/CVD in those who are deficient, VITAL's population (only 12.7% had levels <20 ng/mL) may have been too healthy to demonstrate a benefit, potentially leading to a 'null' result that doesn't apply to deficient populations.
Does the VITAL trial provide sufficient evidence to change the USPSTF 'I' (Insufficient) statement regarding the use of multivitamins or single nutrients for the primary prevention of cardiovascular disease and cancer?
Key Response
VITAL provides high-quality Level 1 evidence that for the general population, these supplements do not offer benefit. While current USPSTF guidelines remain 'Insufficient' due to varying results across smaller trials, VITAL serves as the definitive large-scale RCT that supports a recommendation against routine use for primary prevention in non-deficient adults, moving the needle toward a 'D' (Recommendation against) or a more firm 'No benefit' stance.
Clinical Landscape
Noteworthy Related Trials
GISSI-Prevenzione Trial
Tested
Omega-3 acid ethyl esters 1g daily
Population
Patients with recent myocardial infarction
Comparator
Placebo
Endpoint
Composite of death, non-fatal MI, and stroke
REDUCE-IT Trial
Tested
Icosapent ethyl 4g daily
Population
Patients with established CV disease or diabetes and other risk factors with elevated triglycerides
Comparator
Mineral oil placebo
Endpoint
Composite of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina
D-Health Trial
Tested
Vitamin D3 60,000 IU monthly
Population
Adults aged 60 years or older in Australia
Comparator
Placebo
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis